Acute graft-versus-host disease (aGVHD) is the most common complication of allogeneic bone marrow transplantation (BMT) associated with effector T-cells that result from the recognition of host histocompatibility antigens (both major and minor) by donor T-cells1,2. Despite the use of preventive measures, aGVHD affects 30-70% of recipients and remains a major life-threatening problem in allogeneic transplantation3,4. Thus, there is an urgent need to reveal the mechanism underlying GVHD and to develop the long-term post-transplant outcomes and quality of life of recipients.